10:48 AM EST, 02/27/2025 (MT Newswires) -- BioRestorative Therapies ( BRTX ) said Thursday that the US Food and Drug Administration has cleared its investigational new drug application for BRTX-100 to potentially treat chronic cervical discogenic pain.

BioRestorative Chief Executive Officer Lance Alstodt said the company is planning to carry out a phase 2 study to evaluate BRTX-100's safety and preliminary efficacy in patients with chronic cervical discogenic pain "as soon as is practicable."

Price: 1.87, Change: -0.04, Percent Change: -2.09